Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMP-IT RCT
NL-OMON60247Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of floxuridine in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall Survival. Started Nov 2024; status: recruiting.
02
Drugs
floxuridine
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on NL-OMON60247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60247.